AAAAAA
Results:
1-18
|
Results: 18
Authors:
Junot, C
Pruvost, A
Creminon, C
Grognet, JM
Benech, H
Ezan, E
Citation: C. Junot et al., Characterization of immunoreactive acetyl-Ser-Asp-Lys-Pro in human plasma and urine by liquid chromatography-electrospray mass spectrometry, J CHROMAT B, 752(1), 2001, pp. 69-75
Authors:
Althaus, M
de Mey, C
Ezan, E
Ciecko-Michalska, I
Kostka-Trabkal, E
Goszcz, A
Retzow, A
Citation: M. Althaus et al., Plasma and urine, pharmacokinetics of the dopamine agonist alpha-dihydroergocryptine in patients with hepatic dysfunction, INT J CL PH, 39(2), 2001, pp. 67-74
Authors:
Ezan, E
Delestre, L
Legendre, S
Riviere, R
Doignon, JL
Grognet, JM
Citation: E. Ezan et al., Immunoassays for the detection of nicergoline and its metabolites in humanplasma, J PHARM B, 25(1), 2001, pp. 123-130
Authors:
Junot, C
Gonzales, MF
Ezan, E
Cotton, J
Vazeux, G
Michaud, A
Azizi, M
Vassiliou, S
Yiotakis, A
Corvol, P
Dive, V
Citation: C. Junot et al., RXP 407, a selective inhibitor of the N-domain of angiotensin I-convertingenzyme, blocks in vivo the degradation of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro with no effect on angiotensin I hydrolysis, J PHARM EXP, 297(2), 2001, pp. 606-611
Authors:
de Mey, C
Althaus, M
Ezan, E
Retzow, A
Citation: C. De Mey et al., Erythromycin increases plasma concentrations of alpha-dihydroergocryptine in humans, CLIN PHARM, 70(2), 2001, pp. 142-148
Authors:
Rhaleb, NE
Peng, HM
Yang, XP
Liu, YH
Mehta, D
Ezan, E
Carretero, OA
Citation: Ne. Rhaleb et al., Long-term effect of N-acetyl-seryl-aspartyl-lysyl-proline on left ventricular collagen deposition in rats with 2-kidney, 1-clip hypertension, CIRCULATION, 103(25), 2001, pp. 3136-3141
Authors:
Granveau-Renouf, S
Valente, D
Durocher, A
Grognet, JM
Ezan, E
Citation: S. Granveau-renouf et al., Microdialysis study of bromocriptine and its metabolites in rat pituitary and striatum, EUR J DRUG, 25(2), 2000, pp. 79-84
Authors:
Machard, S
Theodoro, F
Benech, H
Grognet, JM
Ezan, E
Citation: S. Machard et al., A sensitive amphotericin B immunoassay for pharmacokinetic and distribution studies, ANTIM AG CH, 44(3), 2000, pp. 546-550
Authors:
Cole, J
Ertoy, D
Lin, HC
Sutliff, RL
Ezan, E
Guyene, TT
Capecchi, M
Corvol, P
Bernstein, KE
Citation: J. Cole et al., Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice, J CLIN INV, 106(11), 2000, pp. 1391-1398
Authors:
Stephan, JP
Melaine, N
Ezan, E
Hakovirta, H
Maddocks, S
Toppari, J
Garnier, DH
Wdzieczak-Bakala, J
Jegou, B
Citation: Jp. Stephan et al., Source, catabolism and role of the tetrapeptide N-Acetyl-Ser-Asp-Lys-Pro within the testis, J CELL SCI, 113(1), 2000, pp. 113-121
Authors:
Chisi, JE
Briscoe, CV
Ezan, E
Genet, R
Riches, AC
Wdzieczak-Bakala, J
Citation: Je. Chisi et al., Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation, BR J HAEM, 109(3), 2000, pp. 563-570
Authors:
Ezan, E
Grassi, J
Citation: E. Ezan et J. Grassi, Optimization, PRACT APPR, 2000, pp. 187-210
Authors:
Struthers, AD
MacFadyen, R
Fraser, C
Robson, J
Morton, JJ
Junot, C
Ezan, E
Citation: Ad. Struthers et al., Nonadherence with angiotensin-converting enzyme inhibitor therapy - A comparison of different ways of measuring it in patients with chronic heart failure, J AM COL C, 34(7), 1999, pp. 2072-2077
Authors:
Li, XM
Ezan, E
Bindoula, G
Soulard, C
Liu, XH
de Paillette, ED
Levi, F
Citation: Xm. Li et al., Chronopharmacologic aspects of continuous AcSDKP infusion in mice, EXP HEMATOL, 27(1), 1999, pp. 19-27
Authors:
Azizi, M
Ezan, E
Reny, JL
Wdzieczak-Bakala, J
Gerineau, V
Menard, J
Citation: M. Azizi et al., Renal and metabolic clearance of N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) during angiotensin-converting enzyme inhibition in humans, HYPERTENSIO, 33(3), 1999, pp. 879-886
Authors:
Junot, C
Nicolet, L
Ezan, E
Gonzales, MF
Menard, J
Azizi, M
Citation: C. Junot et al., Effect of angiotensin-converting enzyme inhibition on plasma, urine, and tissue concentrations of hemoregulatory peptide acetyl-Ser-Asp-Lys-Pro in rats, J PHARM EXP, 291(3), 1999, pp. 982-987
Authors:
Junot, C
Menard, J
Gonzales, MF
Michaud, A
Corvol, P
Ezan, E
Citation: C. Junot et al., In vivo assessment of captopril selectivity of angiotensin I-converting enzyme inhibition: Differential inhibition of acetyl-Ser-Asp-Lys-Pro and angiotensin I hydrolysis, J PHARM EXP, 289(3), 1999, pp. 1257-1261
Authors:
Boulanger, CM
Ezan, E
Masse, F
Mathieu, E
Levy, BI
Azizi, M
Citation: Cm. Boulanger et al., The hemoregulatory peptide N-acetyl-ser-asp-lys-pro impairs angiotensin I-induced contractions in rat aorta, EUR J PHARM, 363(2-3), 1998, pp. 153-156
Risultati:
1-18
|